




Protecting public health  
with innovative  
*vaccines*

Chasing the *miracles* of science  
to improve people's lives

sanofi



# *Contents*

<i>03</i> Our purpose	<i>09</i> Our vaccine R&D
<i>04</i> Dream Big, vaccines protect us	<i>11</i> Our industrial footprint in vaccines
<i>05</i> Sanofi's vaccines in numbers	<i>13</i> Our partnerships
<i>06</i> Our immunization portfolio	<i>14</i> Delivering on Environmental and Sustainability Goals
<i>07</i> Our technologies	

# Our *purpose*

## Protecting public health with innovative vaccines

Sanofi has been a leader in vaccines for over 100 years: the combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did. Our determination to improve public health motivates us to develop new vaccines to address still unmet medical needs.

Fueled by new data and digital technologies, our science and manufacturing have the potential to transform the practice of medicine for millions of people around the world. And when we discover the extraordinary, we're already planning where to go next. Because everyone deserves a chance to plan for their future, to dream big.

### Davide's Story

Davide is an inspirational athlete and meningitis survivor. He shares his story to help raise awareness about prevention of this potentially devastating infection.

*“ I was not vaccinated, so I was unprotected against meningitis. Now, as a national ambassador of the Spanish Association Against Meningitis, my advice is to vaccinate against this terrible disease. ”*

# Dream Big, *vaccines protect us*

Vaccines help defend us from diseases and let us focus on a future filled with hope. They give us the chance to appreciate the little things that make our day, and dream about the big ones that rock our world. Countless people protected. Countless dreams pursued.

“ Giving birth was, in fact, the making of the real me. I found it empowering, despite even going through a miscarriage. I realized that sense of empowerment in childbirth was integral to my goal of happiness. So, I changed careers, left my job as a journalist in London, and focused on helping other parents feel empowered by their birth experiences. My dream is that all new parents go into a birth informed and educated so that they make the right decisions for them. ”

Georgia, UK

# Sanofi's vaccines *in numbers*



“ From helping to prevent infectious diseases at every stage of life, to protecting humanity against emerging epidemics, vaccines help to create and maintain healthy communities that keep life moving forward.

**Paul Hudson**

Chief Executive Officer

“ We supply millions of vaccine doses for many diseases every day, making it possible to vaccinate over half a billion people worldwide, each year.

**Thomas Triomphe**

Executive Vice President, Vaccines

We are a worldwide leader *in human vaccines*!



**500 million**  
people vaccinated annually  
with our vaccines worldwide



**13** vaccine manufacturing sites  
in 8 countries



**2.5 million** doses of  
vaccines produced daily



**7.2 billion €**  
in sales in 2022, representing  
+6.3% sales growth



Our vaccines  
are available in about  
**150 countries**



**1 billion €**  
invested in vaccines R&D  
each year



**395 million**  
polio vaccine doses supplied  
to UNICEF since 2014



**A world leader**  
in influenza and pediatric  
vaccines

# Our immunization *portfolio*

We are the leader in pediatric combination vaccines, including 6-in-1 hexavalent shots that help protect against diphtheria, tetanus, polio, pertussis, Hib and hepatitis B.

We provide booster vaccines for children, adolescents and adults, extending protection against several life-threatening diseases throughout life. Our pertussis booster vaccine was the first indicated in pregnancy for the prevention of this disease in young infants.

We are the leader in influenza vaccines: our portfolio includes vaccines that can help protect against

flu but also against its potential complications such as heart attacks<sup>2</sup>.

We provide vaccines to help protect against invasive meningococcal disease, a bacterial infection which can have devastating consequences in 24 to 48 hours<sup>3</sup>.

And, through an innovative global partnership, we offer a protective option for infants against Respiratory Syncytial Virus (RSV) a common respiratory disease which is a leading cause of hospitalization in children under one year of age<sup>4,5</sup>.

## Infectious diseases we offer protection against:



Bacterial Infections




Viruses

**Cosmos Okoli** - Polio survivor

*“ I survived Polio when I was four years old... If a vaccine had been available, I would have been vaccinated. I don't want to see any child with polio deformities. It hurts me because it shouldn't happen, as there is a way to stop it. ”*

# Our *technologies*


We use a wide range of tools to develop vaccines that can target proteins, sugars (polysaccharides), or other features that enable viruses and bacteria to thrive in the human body. We are developing vaccines by leveraging different technologies:



## Inactivated vaccines

Inactivated vaccines use the killed version of the germ that causes a disease.


Ex.: Polio, rabies, influenza



## Polysaccharide-based vaccines

Some disease-causing bacteria have a coating made of polysaccharides (sugars) that protects them from being seen and destroyed by cells in our immune system. Using one of these sugars in the vaccine alerts the body to kill the bacteria.


Ex.: Typhoid fever



## Conjugated-polysaccharide vaccines

To help the body remember the bacteria longer and to stimulate a better immune response in children, the sugar is linked to a protein.

Ex.: Invasive disease caused by *Neisseria meningitidis* (serogroups A, C, W, Y), *Haemophilus influenzae* type b in infants.



## Live-attenuated vaccines

Some vaccines are based on weakened whole viruses, which help the body build its defenses without causing disease.

Ex.: Yellow fever




Nikita Khadse and Natalia Vargas -  
Research & Biomarkers lab - mRNA -  
Waltham - Massachusetts - United States



### Recombinant protein vaccines

When only part of a pathogen, like a protein, is needed to create a vaccine, sometimes the right approach is to synthesize that protein using recombinant technology. This involves producing the protein in the lab and formulating it into a vaccine.


Ex.: Hepatitis B and one of our influenza vaccines



### Monoclonal antibody

Rather than stimulating the body to produce its own antibodies, we can design monoclonal antibodies that can offer protection against certain diseases. This kind of rapid protection could bridge important gaps in immunity, especially among very young infants and other at-risk populations.

Ex.: RSV for infants



### Messenger RNA vaccines

mRNA carries messages that instruct human cells to directly manufacture the antigen (e.g. a well identified protein from a virus), in the body, which stimulates the immune system to produce protective antibodies. The mRNA instructions are protected by a lipid barrier to shield it from destructive enzymes and shuttle it into cells.

Ex.: Investigational vaccines for influenza, RSV for adults, chlamydia

> MAKING VACCINES

*Lipid Nano Particles*

Making vaccines

The role of Lipid Nanoparticles (LNPs)



# Our vaccine *R&D*

We invest *more than €1 billion in vaccines R&D annually*.  
Our most exciting current R&D avenues include:

- Investing in mRNA to accelerate the delivery of effective vaccines for stubborn pathogens: our mRNA Center of Excellence (CoE) is focused on tolerability and thermostability of next-generation mRNA vaccines. The CoE houses 400 colleagues across research sites in France and the United States, all concentrated on adapting mRNA technologies from pandemic to routine use across several different disease areas.
- Developing novel vaccines in areas of continued unmet need: RSV vaccines for toddlers and older adults; a pentavalent meningococcal vaccine with broad strain coverage; next-generation influenza vaccines; a pneumococcal vaccine candidate covering more stereotypes than today's licensed vaccines; and next-generation rabies and yellow fever vaccines.



Nick Clark - Research & Biomarkers lab - mRNA - Waltham - Massachusetts - United States

- Pioneering new areas of development, including early-stage research for first-ever vaccines against chlamydia and acne.
- Expanding our leadership in R&D with a full suite of development platforms designed to improve antigen design with the help of artificial intelligence and other digital technologies.

## How does *mRNA work*?

We never stop innovating. We constantly pursue progress, turning science into vaccines that help protect people and communities around the world.

In all, we aim to have 10 new vaccines in clinical trials by 2025, including 6 mRNA technologies.

## The *mRNA* Center of Excellence

We're using mRNA with the goal of developing new, life-saving vaccines and to address long-standing challenges in cancer, immune-mediated diseases, and rare diseases.

Our teams are working to develop mRNA vaccine candidates with a focus on thermostability and tolerability.

- **Tolerability**

Limiting the frequency and severity of side effects.

- **Thermostability**

Developing vaccines that are stable within a wide range of temperatures, making it easier to transport them over long distances and store them for longer periods of time.



Camille Firmann - Assistant Project Manager for mRNA vaccine formulation - Marcy-l'Étoile - France




Approximately **€500 million** investment annually to accelerate end-to-end R&D of next-generation vaccines



A focus on **innovating mRNA vaccines** beyond the pandemic context to routine use in disease areas with unmet medical needs



**6 clinical candidate** using mRNA technologies by 2025



### Optimize mRNA platform technology: *Translational Science Hub*

Partnering with universities and governments to create unique collaborations: The Translational Science Hub (TSH) is working closely with the Center of Excellence (CoE) to convert observations in the laboratory into clinical trials. It connects world-class researchers in Queensland (Australia) with Sanofi scientists in France and the US, creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science.




Maël le Corre - USP Technician - Vitry - France

# Our industrial *footprint* in vaccines

## *Innovate* in production

Our manufacturing sites are powered by big data and digital technology. They are the bridge between scientific advancement and transformative medicine serving millions of people around the world.

In 2023, we produce vaccines across *13 manufacturing sites*. We will add *2 EVolutive Facilities* to that industrial footprint by 2025.



## *EVolute* Facilities

We are digitizing our industrial footprint, modernizing our diversified network and transforming our sites into factories of the future where objects, infrastructure and people are connected.

Digital transformation improves performance, ensures reliability of production and customer service, delivers consistent compliance and quality across our products, and adapts our processes to fluctuations in demand, user needs, and logistics.



Future EVolute Facilities  
for Vaccine Manufacturing -  
Neuville-sur-Saône - France



**About 12 days**

to switch from manufacturing  
one vaccine to another



**50 weeks**

of production per year



**Up to 4 vaccines**

can be produced simultaneously  
on a single production site



**100%**

of the electric consumption  
comes from *renewable energy*

We are adding two new EVolute Facilities (EVF) to our global industrial footprint, one in France and the other in Singapore.

These production units represent the future of vaccine manufacturing. They allow us to increase our capacities while making production more flexible and respectful of the environment.

# Our *partnerships*

External collaborations play a major role in Sanofi's pipeline development. Over the years, we have transformed patients' lives by delivering breakthrough medicines, working in close partnership with other innovators.

Together we can be more ambitious in clinical development, bring products to more patients in more geographies, and create a powerful ecosystem supporting our medicines.



Véronique Chiavazza and  
Séverine Nury - R&D lab -  
Marcy-l'Étoile - France

In some of our most important efforts, *we have partnered* to ensure impact *in public health worldwide*.



## *Access to Vaccines*

We work with the GPEI in the polio eradication effort.



## *Life course immunization*

We team up with industry trade associations like the IFPMA to raise awareness and access to vaccines for people throughout life.



## *Disease surveillance*

We partner with the GISRS to conduct and report on influenza epidemiology.



## *R&D Partners*

We join forces with public and private research organizations in early-stage vaccine discovery.



## *Pandemic preparedness*

Our pandemic preparedness is founded in collaborations with the US BARDA and EU HERA.

GPEI: Global Polio Eradication Initiative

IFPMA: International Federation of Pharmaceutical Manufacturers & Associations

GISRS: Global Influenza Surveillance and Response System

US BARDA: US Biomedical Advanced Research and Development Authority

EU HERA: European Health Emergency Preparedness and Response Authority

# Delivering on *Environmental* and *Sustainability Goals*

We contribute to Sanofi's industry-leading Environmental and Sustainability Goals in several ways:



In the workplace and beyond, *we're ensuring diverse leadership in our company* and strong social and economic engagement in the communities we serve.



*We are continuously improving our efficiency and sustainability by moving to reduced-plastic packaging*, aiming to save 330 tons of plastic per year and having 100% blister-free vaccines by 2027.



*We aim to move to 100% renewable energy across all of our manufacturing sites by 2030* to reduce our carbon footprint and contribute to a healthier planet.



*We support the fight to eradicate polio*, including supplying more than 45 million doses of polio vaccines to UNICEF\* for countries which need it most. This is in addition to the 2.4 billion doses of inactivated polio vaccines we've delivered to the world, either as standalone IPV vaccines or as part of pediatric combination shots.

\* Total IPV-containing vaccines (combo or stand-alone) delivered worldwide to the United Nations International Children's Emergency Fund (UNICEF) since 1981.



Fatima Mohamed Bello - Community Health worker -  
Ogudu Primary Health Center - Lagos - Nigeria

## References:

1. Internal data - June 2023
2. Macintyre C. R., Mahimbo A., Moa A. M., & Barnes M. (2016). Influenza vaccine as a coronary intervention for prevention of myocardial infarction. *Heart*, 102(24), 1953-1956; doi: [10.1136/heartjnl-2016-309983](https://doi.org/10.1136/heartjnl-2016-309983)
3. World Health Organization [Meningitis](#). Accessed September 2023.
4. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. *The Pediatric infectious disease journal*. 2002;21(7):629-32; doi: [10.1097/00006454-200207000-00005](https://doi.org/10.1097/00006454-200207000-00005)
5. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. *Journal of perinatology: official journal of the California Perinatal Association*. 2016;36(11):990-6; doi: [10.1038/jp.2016.113](https://doi.org/10.1038/jp.2016.113)

## Photo credits:

Cover: © Getty Images - P.2: © Sanofi - P.3: © Bleunuit - P.4: © Weber Shandwick - P.5: © Jean Chiscano - © Pierre Olivier/Capa Pictures - P.6: © Bambasi Prod - P.7: © David Parnes - P. 9: © David Parnes - P.10: © Jean Fotso - © Sanofi - P.11: © Pierre Olivier/Capa Pictures - P.12: © Sanofi/PM Group - P.13: © Jean Fotso - P.14: © Bambasi Prod



**.sanofi**